- Home
- BVFL vs CRVS Comparison
BVFL vs CRVS Comparison
Compare BVFL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BVFL | CRVS |
|---|---|---|
| Founded | 1873 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.2M | 634.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BVFL | CRVS |
|---|---|---|
| Price | $18.28 | $7.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | 20.8K | ★ 1.6M |
| Earning Date | 01-26-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $38,669,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.36 | ★ N/A |
| Revenue Growth | ★ 1.69 | N/A |
| 52 Week Low | $13.53 | $2.54 |
| 52 Week High | $19.74 | $9.60 |
Technical Indicators
Market Signals| Indicator | BVFL | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 44.45 |
| Support Level | $18.93 | $7.34 |
| Resistance Level | $19.74 | $8.00 |
| Average True Range (ATR) | 0.50 | 0.52 |
| MACD | -0.19 | -0.12 |
| Stochastic Oscillator | 23.61 | 18.42 |
Price Performance
Historical ComparisonAbout BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).